MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis

被引：1
|
作者：
Goetz, Matthew P. [1 ]
Martin, Miguel [2 ,3 ]
Di Leo, Angelo [4 ]
Im, Seock-Ah [5 ]
Awada, Ahmad [6 ]
Forrester, Tammy [7 ]
Frenzel, Martin [7 ]
Cox, Joanne [8 ]
Barriga, Susana [9 ]
Toi, Masakazu [10 ]
Iwata, Hiroji [11 ]
Johnston, Stephen [12 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Geicam, Inst Invest Sanitaria Gregorio Maranon, Ciberonc, Madrid, Spain
[3] Univ Complutense, Madrid, Spain
[4] Hosp Prato, Prato, Italy
[5] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea
[6] Jules Bordet Inst, Brussels, Belgium
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Eli Lilly & Co, Windlesham, Surrey, England
[9] Eli Lilly & Co, Madrid, Spain
[10] Kyoto Univ, Kyoto, Japan
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT040
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Toxicity of abemaciclib plus endocrine therapy for HR+HER2-advanced breast cancer in Caucasian patients - pooled analysis from MONARCH 2 and 3 trials
    Kisro, J.
    Ettl, J.
    Korfel, A.
    Herbertz, S.
    Stoffregen, C.
    Huober, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 162 - 162
  • [32] Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2-advanced breast cancer (ABC) who progressed on endocrine therapy
    Kaufman, Peter A.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Price, Gregory L.
    Lin, Yong
    Boye, Mark
    Li, Li
    Gable, Jonathon
    Carter, Gebra Cuyun
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2-advanced breast cancer
    Bardia, A.
    Modi, S.
    Oliveira, M.
    Campone, M.
    Ma, B.
    Dirix, L.
    Weise, A.
    Nardi, L.
    Zhang, V.
    Bhansali, S. G.
    Hewes, B.
    Chavez-MacGregor, M.
    CANCER RESEARCH, 2016, 76
  • [34] Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2-advanced breast cancer
    Hao, Chunfang
    Bai, Xuedong
    Zhang, Jie
    Meng, Wenjing
    Tong, Zhongsheng
    THORACIC CANCER, 2023, 14 (01) : 68 - 72
  • [35] Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
    Stephen Johnston
    Joyce O’Shaughnessy
    Miguel Martin
    Jens Huober
    Masakazu Toi
    Joohyuk Sohn
    Valérie A. M. André
    Holly R. Martin
    Molly C. Hardebeck
    Matthew P. Goetz
    npj Breast Cancer, 7
  • [36] Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR-positive (HR+), HER2-negative (HER2-) advanced breast cancer
    Goetz, M. P.
    Johnston, S.
    Martin, M.
    Tokunaga, E.
    Park, I. H.
    Huober, J.
    Toi, M.
    Price, G. L.
    Boye, M.
    Li, L.
    Forrester, T.
    Gainford, C.
    Gable, J.
    Carter, G. C.
    Sood, A.
    Dileo, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 288 - 289
  • [37] Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
    Johnston, Stephen
    O'Shaughnessy, Joyce
    Martin, Miguel
    Huober, Jens
    Toi, Masakazu
    Sohn, Joohyuk
    Andre, Valerie A. M.
    Martin, Holly R.
    Hardebeck, Molly C.
    Goetz, Matthew P.
    NPJ BREAST CANCER, 2021, 7 (01)
  • [38] Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding " Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2-advanced breast cancer: final overall survival results of MONARCH 3" by M. P. Goetz et al.
    Sherry, A. D.
    Lin, T. A.
    McCaw, Z. R.
    Ludmir, E. B.
    ANNALS OF ONCOLOGY, 2024, 35 (08) : 747 - 748
  • [39] Therapy of HR+/HER2-advanced or metastatic Breast Cancer Palbociclib: Importance of Data from Everyday Care for Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [40] Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HRD, HER2L advanced breast cancer: final overall survival results of MONARCH 3
    Goetz, M. P.
    Toi, M.
    Huober, J.
    Sohn, J.
    Tredan, O.
    Park, I. H.
    Campone, M.
    Chen, S. -C.
    Manso, L. M.
    Paluch-Shimon, S.
    Freedman, O. C.
    O'Shaughnessy, J.
    Pivot, X.
    Tolaney, S. M.
    Hurvitz, S. A.
    Llombart-Cussac, A.
    Andre, V.
    Saha, A.
    van Hal, G.
    Shahir, A.
    Iwata, H.
    Johnston, S. R. D.
    ANNALS OF ONCOLOGY, 2024, 35 (08) : 718 - 727
12345